Story

Novo Nordisk Stock Slides After Berenberg Downgrade Cites Eli Lilly Competition

ENTHMSVIIDZHZH-TWJAKOHI
Aug 12, 20262 min read
Novo Nordisk Stock Slides After Berenberg Downgrade Cites Eli Lilly Competition
Text size
Background

Shares of Novo Nordisk A/S (NOVOb) declined sharply in Tuesday trading after analysts at Berenberg downgraded the pharmaceutical giant, pointing to a fully realized growth narrative and mounting competitive pressure from rival Eli Lilly.

Berenberg Lowers Rating to 'Hold'

Berenberg lowered its rating on Novo Nordisk to 'Hold' from 'Buy' and reduced its Copenhagen-listed price target to DKK 305 from DKK 325. The move marks a shift from the firm's previously bullish stance on the stock.

According to the analyst note from Kerry Holford, the investment thesis that supported the 'Buy' rating has "fully run its course." Berenberg argued that the expected upside from the oral version of its blockbuster weight-loss drug, Wegovy, has already been factored into the stock's price. The note stated that both the firm and the broader market consensus now forecast approximately DKK 15 billion in 2026 sales for the Wegovy pill, leaving little room for positive surprises.

Intensifying Competition from Eli Lilly

The downgrade centered on the growing competitive threat posed by U.S. rival Eli Lilly in the lucrative GLP-1 drug market. Berenberg's analysis suggested that Lilly is positioned to benefit disproportionately as U.S. Medicare begins providing access to weight-loss medications.

Sample IUX Markets – In-articleAd

Adding to the competitive headwinds, Berenberg flagged the imminent FDA approval of Lilly’s oral diabetes pill, which is expected to amplify its direct-to-consumer advertising and further challenge Novo Nordisk’s market share. The competitive narrative was reinforced by the UK's regulatory approval of Lilly's Foundayo pill on Tuesday.

Market Reaction

In response to the downgrade, Novo Nordisk shares fell 3.4% to trade at DKK 296.7 during the session. The stock's weakness was specific to the company, as broader U.S. equity benchmarks like the S&P 500 and Nasdaq were trading higher.

The analyst action comes just days after a mixed market reaction to Novo Nordisk's second-quarter earnings, suggesting investors are reassessing the stock's near-term upside amid the shifting competitive landscape.

Read next

More on Stocks
Back to latest news

LATEST